Biotechnology
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on ...
2022-02-18 08:19
2176
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's Lymphoma
SUZHOU, China and PALO ALTO, Calif., Feb. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...
2022-02-17 21:30
3057
Flat Medical joins the Stay Connected(R), the International Organization for Safer Neuraxial Anesthesia
TAIPEI, Feb. 17, 2022 /PRNewswire/ -- Flat Medical Co., Ltd., a MedTech company specializing in safety solutions for anesthesia and critical care procedures, has announced that it has just joined the Stay Connected®, a joint communication initiative on behalf of the industry to advocate and educa...
2022-02-17 21:00
1988
PharmaBlock Appoints Dr. Zhengtian Gu as Senior Vice President of Quality and Regulatory Affairs
NANJING, China, Feb. 16, 2022 /PRNewswire/ -- PharmaBlock (300725.SZSE), an innovative chemistry products and services provider to support drug discovery, development, and commercialization, announces the appointment of Dr. Zhengtian (Titan) Gu as Senior Vice President of Quality and Regulatory A...
2022-02-16 20:00
2023
Travecta Therapeutics Appoints Leading Experts to Expand its Scientific Advisory Leadership Team
PRINCETON, N.J. and SINGAPORE, Feb. 15, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a preclinical stage biopharmaceutical company pioneering a portfolio of product candidates engineered to cross the blood-brain-barrier, today announced significant expansion of the Scientific Advisory B...
2022-02-15 21:00
1932
HPG: New Breakthrough in Virus Inactivation with Green Tea Catechin (EGCg)
TOKYO, Feb. 15, 2022 /PRNewswire/ -- HPG Co., Ltd. (Chuo-ku, Tokyo) has successfully developed a water-soluble formulation technology of highly concentrated catechin EGCg (Epigallocatechin gallate) with excellent storage stability and initiated procedures for a patent application for the technolo...
2022-02-15 16:00
1800
Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient inChina in its multi-regi...
2022-02-11 20:40
4855
WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 10, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champi...
2022-02-11 10:00
2468
Ucello Therapeutics Completes US$25 Million Series A Financing
SAN DIEGO, Calif. and CHENGDU, China, Feb. 10, 2022 /PRNewswire/ -- Ucello Therapeutics ("Ucello"), a biotechnology company developing universal CAR-T therapies, announced the successful completion of aUS$25 million Series A financing. The funding round was led by Matrix Partners China, alon...
2022-02-11 02:16
2596
AKESO'S NGF MONOCLONAL ANTIBODY (AK115) APPROVED TO INITIATE CLINICAL TRIAL IN PAIN (INCLUDING CANCER PAIN)
HONG KONG, Feb. 10, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the clinical trial application of the innovative nerve growth factor (NGF) monoclonal antibody (research and development code: AK115) injection developed in-house by the Company, has obtained approval from the Centre fo...
2022-02-10 17:00
2710
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
* Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health * Data shows that 51% of participants achieved sustained unresponsiveness (clinical remission) to peanut after 18 months of treatment * Prota Therapeutics announces new round of capital raising for fur...
2022-02-09 20:00
1983
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
HONG KONG, Feb. 9, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for evaluation of the safety, tolerability and anti-...
2022-02-09 17:12
2221
Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics
* Two-year research collaboration to develop new reactive group chemistries targeting non-cysteine amino acids to expand druggable binding sites and identify novel targets in oncology and immunology * Collaborators at Scripps are pioneers in the field of chemical biology and chemistry SEONGNA...
2022-02-08 06:00
2402
IonOpticks enters OEM partnership with Bruker that sets a new standard for mass spectrometry-based research
MELBOURNE, Australia, Feb. 7, 2022 /PRNewswire/ -- Premium manufacturer of chromatography for proteomics applications, IonOpticks, has entered an OEM partnership with the Bruker Corporation (Nasdaq: BRKR), allowing Bruker to expand their portfolio of 4D-Proteomics solutions with the release of th...
2022-02-08 00:01
2594
Samsung Biologics receives 2022 CMO Leadership Award in all six categories
INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...
2022-02-07 20:00
2814
Laekna Launched the new domain name www.laekna.com
SHANGHAI and WARREN, N.J., Feb. 6, 2022 /PRNewswire/ -- Laekna Group (Laekna Inc and all its direct or indirect subsidiaries, including Laekna Therapeutics Shanghai Co., Ltd.), an emerging innovative biotech based inChina's "Zhangjiang Pharma Valley" andNew Jersey in the U.S. and focused on devel...
2022-02-07 12:47
1890
Genesis MedTech Acquires JC Medical, Creates New Structural Heart Franchise
SINGAPORE, Feb. 4, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment ...
2022-02-05 08:00
5028
Novotech Recognized as Top 10 CRO in CenterWatch Site Relationship Benchmarking Report
SYDNEY, Feb. 4, 2022 /PRNewswire/ -- Novotech, the leading Asia Pacific biotech
specialist CRO, has been recognized as a top 10 CRO in the2021 CenterWatch
Global Site Relationship Benchmark Survey. Report available here
2022-02-04 19:47
4237
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...
2022-02-04 06:54
3217
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it had reached an agreement with TheScripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps...
2022-02-03 22:00
2337
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 316 media titles]
2026-05-28 15:06Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 291 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 290 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 285 media titles]
2026-05-28 14:10
DayOne Appoints Nicolas Aguzin to Board of Directors, Strengthening Global Governance and Capital Markets Expertise
[Picked up by 281 media titles]
2026-05-29 15:50Most Read
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
7381
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
7077
